Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH 2), a beta integrin antagonist, in patients with solid tumours

British Journal of Cancer

Volumn 94, Issue 11, 2006, Pages 1621-1626

  Cianfrocca, M E ^a   Kimmel, K A ^b   Gallo, J ^a   Cardoso, T ^a   Brown, M M ^a   Hudes, G ^a   Lewis, N ^a   Weiner, L ^a   Lam, G N ^d   Brown, S C ^b   Shaw, D E ^c   Mazar, A P ^b   Cohen, R B ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b Attenuon LLC   (United States)

^c D E SHAW RESEARCH   (United States)

^d MicroConstants Inc   (United States)

Author keywords

5 1 integrin; v 3 integrin; Angiogenesis; ATN 161; Phase 1 trial

Indexed keywords

ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINAMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ATN 161; BETA INTEGRIN ANTAGONIST; INTEGRIN ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG URINE LEVEL; FATIGUE; FEMALE; HUMAN; HYPOTENSION; LIMB PAIN; MALE; MUSCLE CRAMP; NAUSEA; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; SOLID TUMOR; SWEATING; THRUSH; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OLIGOPEPTIDES;

EID: 33745240059     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603171     Document Type: Article

References (41)

1. Ahmed SI, Thomas AL, Steward WP (2004) Vascular endothelial growth factor (VEGF) inhibition by small molecules. J Chemother 16(Suppl 4):59-63
2. Aota S, Nomizu M, Yamada KM (1994) The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J Biol Chem 269: 24756-24761
3. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63: 4342-4346
4. Brooks PC (1996) Role of integrins in angiogenesis. Eur J Cancer 32A: 2423-2429
5. Brooks PC, Clark RA, Cheresh DA (1994a) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571
6. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994b) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164
7. Calabrese EJ, Baldwin LA (2002) Applications of hormesis in toxicology, risk assessment and chemotherapeutics. Trends Pharmacol Sci 23: 331-337
8. Calabrese EJ, Baldwin LA (2003) Chemotherapeutics and hormesis. Crit Rev Toxicol 33: 305-353
9. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257, doi:10.1038/35025215.
10. Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, Corti A (2005) Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res 65: 2906-2913
11. Donate F, Guan X, Callahan JA, Mazar AP, Parry GC (2003) ATN-161 (Ac-PHSCN-NH2) has potent anti-angiogenic activity through multiple mechanisms of action and localizes to newly formed blood vessels in vivo. Proc Am Assoc Cancer Res 44: 63
12. Drolet BA, Esterly NB, Frieden IJ (1999) Hemangiomas in children. N Engl J Med 341: 173-181
13. Eskens F, Dumez H, Verweij J (2000) Phase I and pharmacologic study of Cilengitide (EMD 121974), an αvβ3 and αvβ5 integrin inhibitor that perturbs tumor angiogenesis, in patients with solid tumors. Proc Am Soc Clin Oncol 19: A801
14. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31
15. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50: 219-244
16. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJ (2003) Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21: 2831-2842
17. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA (2000) Targeted antiangiogenic therapy for cancer using vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6: 3056-3061
18. Harris AL (1997) Antiangiogenesis for cancer therapy. Lancet 349(Suppl 2): SII13-SII15
19. Hensley HH, Mazar AP (2003) Evaluation of the anti-angiogenic agent ATN-161 by dynamic magnetic resonance imaging in a mouse model. Proc Am Assoc Cancer Res 44: 59
20. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
21. Kopp WC, Smith II JW, Ewel CH, Alvord WG, Main C, Guyre PM, Steis RG, Longo DL, Urba WJ (1993) Immunomodulatory effects of interferon-gamma in patients with metastatic malignant melanoma. J Immunother 13: 181-190
22. Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Jr, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS (2005) Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 23: 5464-5473
23. Livant DL, Brabec RK, Kurachi K, Allen DL, Wu Y, Haaseth R, Andrews P, Ethier SP, Markwart S (2000a) The PHSRN sequence induces extracellular matrix invasion and accelerates wound healing in obese diabetic mice. J Clin Invest 105: 1537-1545
24. Livant DL, Brabec RK, Pienta KJ, Allen DL, Kurachi K, Markwart S, Upadhyaya A (2000b) Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res 60: 309-320
25. Mitjans F, Meyer T, Fittschen C, Goodman S, Jonczyk A, Marshall JF, Reyes G, Piulats J (2000) In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer 87: 716-723
26. Mould AP, Askari JA, Aota S, Yamada KM, Irie A, Takada Y, Mardon HJ, Humphries MJ (1997) Defining the topology of integrin alpha5beta1-fibronectin interactions using inhibitory anti-alpha5 and anti-betal monoclonal antibodies. Evidence that the synergy sequence of fibronectin is recognized by the amino-terminal repeats of the alpha5 subunit. J Biol Chem 272: 17283-17292
27. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655
28. Parulekar WR, Eisenhauer EA (2004) Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 96: 990-997
29. Perrier D, Gibaldi M (1982) General derivation of the equation for time to reach a certain fraction of steady state. J Pharm Sci 71: 474-475
30. Pierschbacher MD, Ruoslahti E (1984) Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309: 30-33, doi:10.1038/309030a0
31. Plunkett ML, Beck I, Avery J, Tel-Tsur Z, Yu M, Livant DL, Arimura J, Truong F, Mazar AP (2003) Combining low dose chemotherapy with low dose anti-angiogenic agents (ATN-161 and ATN-224) leads to increased anti-tumor activity in prostate cancer xenograft models. Proc Am Assoc Cancer Res 44: 3730
32. Plunkett ML, Mazar AP (2002) Dose and schedule optimization of a novel anti-angiogenic/anti-metastatic peptide, ATN-161 (Ac-PHSCN-NH2), which targets mutiple fully activated integrins including alpha-5 beta-1 and alpha-v beta-3. Eur J Cancer 38(Suppl 7): 82
33. Plunkett ML, Tel-Tsur Z, Bera M, Beck I, Avery J, Livant DL, Mazar AP (2002) A novel anti-angiogenic/anti-metastatic peptide, ATN-161 (Ac-PHSCN-NH2), which targets multiple fully activated integrins including alpha-5 beta-1 and alpha-v beta-3, leads to increased anti-tumor activity and increased survival in multiple tumor models when combined with chemotherapy. Eur J Cancer 38(Suppl 7): 79
34. Rini BI, Sosman JA, Motzer RJ (2005) Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU Int 96: 286-290
35. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ (1999) Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5: 2726-2734
36. Sledge Jr GW (2005) A new age now begins. Clin Breast Cancer 6: 99
37. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA, McCarty MF, Bucana CD, Mazar AP, Ellis LM (2003) Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 104: 496-503
38. Talmadge JE (1998) Pharmacodynamic aspects of peptide administration biological response modifiers. Adv Drug Deliv Rev 33: 241-252
39. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of Canada. J Natl Cancer Inst 92: 205-216
40. Wakelee H, Schiller J (2005) Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. Clin Lung Cancer 7: S31-S38
41. Yan B, Smith JW (2000) A redox site involved in integrin activation. J Biol Chem 275: 39964-39972